Holen Sie sich die Stockscreener-App
41.79
0.46%
0.19
Handel nachbörslich:
41.80
0.010
+0.02%
Schlusskurs vom Vortag:
$41.60
Offen:
$41.76
24-Stunden-Volumen:
2.68M
Relative Volume:
0.70
Marktkapitalisierung:
$100.13B
Einnahmen:
$49.41B
Nettoeinkommen (Verlust:
$5.59B
KGV:
17.50
EPS:
2.3875
Netto-Cashflow:
$8.32B
1W Leistung:
+5.61%
1M Leistung:
+1.65%
6M Leistung:
-10.67%
1J Leistung:
-19.07%
1-Tages-Spanne:
$41.45
$41.89
1-Wochen-Bereich:
$40.84
$42.11
52-Wochen-Spanne:
$39.07
$52.68
Sanofi Adr Stock (SNY) Company Profile
Compare SNY vs LLY, JNJ, ABBV, MRK, NVS
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
SNY
Sanofi Adr
|
41.79 | 100.13B | 49.41B | 5.59B | 8.32B | 2.3875 |
LLY
Lilly Eli Co
|
1,279.14 | 1.14T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
266.30 | 641.07B | 97.93B | 21.04B | 17.80B | 8.6278 |
ABBV
Abbvie Inc
|
286.74 | 506.70B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
140.61 | 346.91B | 65.51B | 8.93B | 14.12B | 3.5532 |
NVS
Novartis Ag Adr
|
153.81 | 292.35B | 54.66B | 13.58B | 16.05B | 7.0171 |
Sanofi Adr Stock (SNY) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-10-09 | Eingeleitet | Wolfe Research | Peer Perform |
| 2026-09-09 | Eingeleitet | RBC Capital Mkts | Sector Perform |
| 2026-05-01 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2026-04-20 | Herabstufung | BNP Paribas Exane | Outperform → Neutral |
| 2026-02-12 | Herabstufung | BofA Securities | Buy → Neutral |
| 2026-01-27 | Eingeleitet | Citigroup | Neutral |
| 2026-01-16 | Herabstufung | UBS | Buy → Neutral |
| 2026-01-06 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2025-12-09 | Herabstufung | Guggenheim | Buy → Neutral |
| 2025-12-08 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2025-09-08 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2025-09-02 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2025-08-08 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2025-04-15 | Eingeleitet | Exane BNP Paribas | Outperform |
| 2025-03-21 | Eingeleitet | Goldman | Neutral |
| 2025-01-30 | Hochstufung | Deutsche Bank | Sell → Hold |
| 2024-07-26 | Bestätigt | Argus | Buy |
| 2024-01-23 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2024-01-16 | Fortgesetzt | UBS | Buy |
| 2023-12-05 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2023-10-30 | Herabstufung | Stifel | Buy → Hold |
| 2023-09-06 | Hochstufung | Berenberg | Hold → Buy |
| 2023-07-14 | Eingeleitet | HSBC Securities | Buy |
| 2023-04-28 | Herabstufung | Deutsche Bank | Hold → Sell |
| 2023-03-27 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2022-12-13 | Fortgesetzt | Morgan Stanley | Overweight |
| 2022-08-12 | Hochstufung | Deutsche Bank | Sell → Hold |
| 2022-08-09 | Herabstufung | UBS | Buy → Neutral |
| 2022-05-23 | Eingeleitet | SVB Leerink | Outperform |
| 2021-09-27 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2021-01-15 | Eingeleitet | Deutsche Bank | Sell |
| 2020-09-29 | Eingeleitet | Berenberg | Hold |
| 2020-03-17 | Hochstufung | Barclays | Underweight → Equal Weight |
| 2020-03-11 | Hochstufung | Goldman | Neutral → Buy |
| 2020-02-11 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2020-01-06 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2019-09-23 | Hochstufung | Guggenheim | Neutral → Buy |
| 2019-09-20 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2019-09-03 | Eingeleitet | Bernstein | Outperform |
| 2019-08-14 | Hochstufung | UBS | Neutral → Buy |
| 2018-12-11 | Hochstufung | Jefferies | Hold → Buy |
| 2018-11-01 | Hochstufung | Barclays | Underweight → Equal Weight |
| 2018-10-09 | Eingeleitet | Guggenheim | Neutral |
| 2018-09-10 | Hochstufung | BofA/Merrill | Neutral → Buy |
| 2018-08-10 | Hochstufung | Citigroup | Neutral → Buy |
| 2018-03-23 | Hochstufung | Liberum | Hold → Buy |
| 2018-01-23 | Herabstufung | Barclays | Equal Weight → Underweight |
| 2017-12-06 | Herabstufung | BofA/Merrill | Buy → Neutral |
| 2017-12-01 | Herabstufung | Morgan Stanley | Overweight → Underweight |
| 2017-11-15 | Hochstufung | Barclays | Underweight → Equal Weight |
| 2017-08-30 | Hochstufung | HSBC Securities | Reduce → Hold |
Alle ansehen
Sanofi Adr Aktie (SNY) Neueste Nachrichten
Colorectal Cancer Market Set for Significant Growth During the Forecast Period (2026–2036), Due to the Emergence of Emerging Targets such as KRAS G12C, NTRK Fusions, and PIK3CA Mutations | DelveInsight - GlobeNewswire Inc.
Alzheimer's Disease Clinical Trial and Competitive Landscape Enters a New Phase as 200+ Companies Advance Clinical Programs | DelveInsight - GlobeNewswire Inc.
GSK's New Drugs and Pipeline Hold the Key to Long-Term Growth - Zacks Investment Research
Forget Eylea: Regeneron's Real Value May Be Hiding in Its Dupixent Profit Share - The Motley Fool
Can Nektar's Pipeline Progress Create Long-Term Value Amid Rivalry? - Zacks Investment Research
Which Pharma Stock Looks More Attractive: Sanofi or AbbVie? - Zacks Investment Research
Matchpoint Therapeutics Expands Leadership Team with Appointment of John O’Malley, M.D., Ph.D., as Chief Medical Officer - GlobeNewswire Inc.
Moderna vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy in 2026? - The Motley Fool
TEVA Gets FDA Nod for Weltruza as Once-Monthly LAI in Schizophrenia - Zacks Investment Research
Retension Pharmaceuticals Announces Pricing of Initial Public Offering - GlobeNewswire Inc.
Press Release : Availability of the aide-mémoire for Q3 2026 results - GlobeNewswire Inc.
Communiqué de presse : Mise en ligne du document «Q3 2026 aide-mémoire » - GlobeNewswire Inc.
Sanofi, Regeneron Expand Immunology Alliance With New Antibodies - Zacks Investment Research
GSK vs. SNY: Which Europe-Based Pharma Stock Has More Potential? - Zacks Investment Research
Enzyme Replacement Therapy Market to Grow to USD 27.90 Billion by 2035 at a CAGR of 8.59%SNS Insider - GlobeNewswire Inc.
Full issuance would represent about 66.67% of Scinai (SCNI)'s depositary shares under its funding deal. - Stock Titan
Sanofi (SNY) Stock Price, News, Quote & History - Yahoo! Finance Canada
Is Regeneron Stock a Bargain Below $800? - The Motley Fool
Recludix Pharma to Present at the Oppenheimer Private Life Sciences Company Showcase - GlobeNewswire Inc.
GSK's Specialty Medicines Drive Growth Amid Looming HIV Patent Cliff - Zacks Investment Research
Sanofi partners with USA Pickleball to launch "Serve Up Protection" campaign to help protect older adults from COVID-19 with NUVAXOVID - Finviz
RBC Capital initiates Sanofi stock at Sector Perform on transition risks - Investing.com Canada
Monoclonal Antibodies Market to Grow at 11.01% CAGR, Reaching USD 791.28 Billion by 2035 – SNS Insider - GlobeNewswire Inc.
Ulcerative Colitis Market Outlook: 5 Late-Stage Drug Candidates to Watch | DelveInsight - GlobeNewswire Inc.
Drug Repurposing Market to Reach USD 50.91 Billion by 2035, Expanding at 3.93% CAGR | SNS Insider - GlobeNewswire Inc.
Atopic Dermatitis Drugs Market Set to Reach USD 33.42 Billion by 2035, at a CAGR of 7.70%SNS Insider - GlobeNewswire Inc.
Sanofi ADSADR Shareholding Pattern – Promoters, FIIs & DIIs - valueresearchonline.com
Sanofi ADSADR Key Financial Ratios – Valuation, Profitability & More - valueresearchonline.com
European ADRs Slipped In US Trading Late Thursday Morning - Finimize
Sanofi-ADR (NASDAQ:SNY): A Dividend Quality Candidate with Solid Profitability - ChartMill
Sanofi stock holds firm as workforce shake-up follows strong Q2 2026 - ad-hoc-news.de
Sanofi stock steadies after strong Q2 2026 and upgraded guidance - Ad-hoc-news.de
Sanofi stock steadies as upgraded 2026 guidance follows strong Q2 momentum - AD HOC NEWS
Sanofi stock climbs as MenQuadfi approval and cuts reshape the story - Ad-hoc-news.de
Sanofi stock edges higher as MenQuadfi approval and workforce reshaping define mid-August story - Ad-hoc-news.de
European ADRs Drift Lower In US Trading - Finimize
Sanofi's New Leadership Faces Looming Patent Cliff - Morningstar
6 Undervalued Stocks That Crushed Earnings - morningstar.com
Resilient Sanofi stock edges higher as Q2 2026 growth and R&D reshuffle shape outlook - Ad-hoc-news.de
Sanofi stock holds steady as India unit boosts profit and secures tax refund - Ad-hoc-news.de
Adagene Reports Six Months 2026 Financial Results and Provides Corporate Updates - Macau Business
Adagene Reports Six Months 2026 Financial Results and Provides Corporate Updates - GlobeNewswire
Trump considers order on autism and vaccines: which stocks are most exposed? - Investing.com
Nurix earns $10m milestone as Sanofi starts STAT6 degrader trial - Investing.com Nigeria
ETFs Investing in Sanofi SA Sponsored ADR Stocks - tradingview.com
Key facts: Sanofi SA Sponsored ADR files H1 2026; halts three drugs - TradingView
What's behind Sanofi's latest 5.4% stock pullback? - tradersunion.com
European ADRs Jump In US Trading As Banks Lead - Finimize
Sanofi ADR earnings beat by $1.30, revenue topped estimates - investing.com
ETFs Investing in Sanofi SA Sponsored ADR Stocks - TradingView
Finanzdaten der Sanofi Adr-Aktie (SNY)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.69%
0.80%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):